Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 9/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312622 | 0.80 | GRM2 (0.38) | SLC9A1GRM2RAB9APTK2 | |
| SCHEMBL14987764 | 0.77 | SLC9A1 (0.57) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL23386958 | 0.74 | SLC9A1 (0.57) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL12204547 | 0.73 | GRM2 (0.64) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL2734889 | 0.72 | GRM2 (1.00) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL14796568 | 0.71 | SLC9A1 (0.79) | SLC9A1GRM2TDP1NPC1MAPT | |
| SCHEMBL27416345 | 0.71 | SLC9A1 (0.57) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL1774497 | 0.70 | SLC9A1 (0.70) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL31234269 | 0.70 | SLC9A1 (0.70) | SLC9A1GRM2TDP1KCNMA1NPC1 | |
| SCHEMBL27415682 | 0.70 | SLC9A1 (0.60) | SLC9A1GRM2TDP1KCNMA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | claimed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | disclosed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | disclosed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GABBR1, ABAT, GABBR2 | SLC9A1 2708/4885GRM2 118/4885TDP1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.